Ma Pepeluali 13, 2026, ua hoʻolaha ke Kikowaena no ka Loiloi Lāʻau Lapaʻau (CDE) o ka ʻOihana Hoʻokele Huahana Lapaʻau Lahui o Kina ua hoʻokomo ʻia nā papa GFH375 i ka Breakthrough Therapy Designation no ka mālama ʻana i nā maʻi me ka maʻi kanesa māmā non-small cell KRAS G12D-mutant (NSCLC) i loaʻa i ka liʻiliʻi o hoʻokahi lāʻau lapaʻau systemic ma mua.
Ke haki nei i ke code o ka pahuhopu "Undruggable"
Ua manaʻo mua ʻia nā hoʻololi ʻana o KRAS e ke kaiāulu lapaʻau he pahuhopu "ʻaʻole hiki ke hoʻōla ʻia". Eia nō naʻe, me ka holomua o ka noiʻi ʻepekema, ke lanakila mālie nei kēia pilikia. ʻO KRAS G12D kekahi o nā ʻano maʻamau o nā hoʻololi ʻana o KRAS, i ʻike pinepine ʻia i ka pancreatic ductal adenocarcinoma (PDAC), ka maʻi ʻaʻai māmā non-small cell (NSCLC), a me ke kanesa colorectal.
Ke paipai nei i ka ʻikepili lapaʻau: Hōʻike ʻo GFH375 i ka hana anti-tumor ikaika
Ua hāʻawi nā ʻikepili lapaʻau mai ka hoʻokolohua Phase I o GFH375 i nā poʻe maʻi me nā ʻōpū paʻa KRAS G12D-mutant holomua, i hōʻike ʻia ma ka 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, i nā hopena hoʻoikaika. Ua hōʻike ka ʻikepili i ka bioavailability waha maikaʻi a me ka hana pale ʻana i ka ʻōpū koho kiʻekiʻe o GFH375. I ka lā palena ʻikepili, ua kākau inoa ʻia he 62 mau poʻe maʻi me nā ʻōpū paʻa KRAS G12D-mutant holomua i mālama mua ʻia i ka hoʻokolohua Phase I o GFH375 monotherapy.
Nā Pūʻulu Dose Target: Ka Pono Koʻikoʻi
Ma waena o 49 mau maʻi i loaʻa i nā mahele waha o 400mg a i ʻole 600mg i kēlā me kēia lā, ua kupaianaha loa ka ʻikepili pono:
Ka helu pane holoʻokoʻa (ORR): I loko o 43 mau maʻi i hiki ke loiloi ʻia, ua hōʻea ka ORR i ka 42%, a ʻo ka helu kāohi maʻi (DCR) ua kiʻekiʻe a hiki i ka 91%.
Nā Maʻi Adenocarcinoma Ductal Pancreatic (PDAC): Ma waena o 23 mau maʻi PDAC hiki ke loiloi ʻia, ʻo ka ORR he 52%, a ua hiki ka DCR i 100%.
Nā Maʻi Kanesa Mama ʻAʻole Liʻiliʻi (NSCLC): Ma waena o 12 mau maʻi NSCLC hiki ke loiloi ʻia, ʻo ka ORR he 42%, a ʻo ka DCR he 83%.
Nā Hui Dose āpau: Hana ākea a koʻikoʻi
I loko o 52 mau maʻi i hoʻopau i ka liʻiliʻi o hoʻokahi loiloi puʻupuʻu ma hope o ka mālama ʻana, ʻo ka ORR ma nā hui lāʻau āpau he 38%, me ka DCR o 90%. ʻIke ʻia, ua ʻike ʻia he 38 mau maʻi i ka emi ʻana o kā lākou mau lesions i manaʻo ʻia, a ua loaʻa i 20 mau maʻi kahi pane hapa. Hōʻike kēia mau ʻikepili mua e hōʻike ana ʻo GFH375 i ka hana pale puʻupuʻu koʻikoʻi i nā maʻi me nā puʻupuʻu paʻa e like me PDAC a me NSCLC, me ka poʻe i holomua ma hope o nā laina he nui o ka lāʻau lapaʻau.
I ke alo ʻana i ia mau holomua lapaʻau hou loa, he mea koʻikoʻi ke koho ʻana i kahi ʻoihana lapaʻau i hiki ke hāʻawi i nā koho lapaʻau holomua a me nā lawelawe piha. Ua hoʻolaʻa ʻia ka ʻOihana Honua ma ka Halemai Oncology ʻĀpana Hema o Beijing i ka hāʻawi ʻana i nā lawelawe ʻike a me ka mālama ʻana i ka maʻi kanesa i nā poʻe maʻi kūloko a me nā poʻe o ka honua. Ke noho nei mākou me ka ʻike hou loa i nā hoʻomohala hou loa i ka noiʻi oncology honua a ua kūpaʻa mākou i ka lawe ʻana mai i nā lāʻau lapaʻau holomua e like me GFH375 i nā poʻe maʻi e pono ai i ka wikiwiki.
ʻO kā mākou mau pono:
Nā Hoʻonā Lapaʻau ʻOi Loa: Ke hoʻomau nei mākou me nā kūlana o ka honua, e kālele ana a me ka hoʻolauna ʻana i nā ʻano lapaʻau holomua e like me GFH375, e hāʻawi ana i nā manawa kūpono e lapaʻau ai no nā poʻe maʻi me nā hoʻololi KRAS G12D.
Hui Loea Multidisciplinary: Hoʻohui mākou i nā loea oncology kūloko kiʻekiʻe e hana pū ana i nā kūkākūkā multidisciplinary e hoʻomohala i nā hoʻolālā lapaʻau pilikino a pololei hoʻi no kēlā me kēia maʻi.
Nā Kūlana Lawelawe Honua: Mai ke kūkākūkā ʻana, ka hoʻonohonoho ʻana i nā manawa, nā lawelawe unuhi a hiki i ke kaʻina hana lapaʻau holoʻokoʻa, hāʻawi mākou i ke kamaʻilio maʻalahi a me ka lawelawe akahele, e hōʻoiaʻiʻo ana i kahi ʻike lapaʻau ʻoluʻolu a hōʻoluʻolu hoʻi no nā poʻe maʻi o ka honua a me ko lākou mau ʻohana.
Kākoʻo Maʻi Piha: Ke hoʻoikaika nei mākou no ka maikaʻi loa ʻaʻole wale i ka mālama ʻana akā ke nānā nei hoʻi i ka pono o ka noʻonoʻo o nā mea maʻi a me ke ʻano o ke ola, e hāʻawi ana i ke kākoʻo a me ka mālama.
E Kāhea iā Mākou i Kēia Manawa e ʻImi i ka Manaʻolana Hou no ka Lāʻau Lapaʻau
Inā ua ʻike ʻia ʻoe a i ʻole kekahi lālā o ka ʻohana me ka maʻi kanesa māmā KRAS G12D-mutant non-small cell a i ʻole nā pūpū paʻa ʻē aʻe a ua loaʻa iā ʻoe kahi pane kūpono ʻole i nā koho lapaʻau e kū nei, e ʻoluʻolu e kelepona i ka ʻOihana Honua ma ka Halemai Oncology ʻĀpana Hema o Beijing. E hāʻawi kā mākou hui loea iā ʻoe i ka ʻike lapaʻau hou loa a me nā ʻōlelo aʻoaʻo pilikino no ka hōʻailona a me ka mālama ʻana.
E ʻoluʻolu e hoʻokaʻaʻike mai iā mākou ma o kēia mau ʻano hana:
Kelepona: 400-880-3716
WeChat: 17801183037
Email: 100085_010@163.com 或 myimmnet@163.com
Mai hoʻokuʻu i nā pale mamao a i ʻole ka ʻōlelo e lilo i mea keakea i kāu ʻimi ʻana i ka lāʻau lapaʻau holomua. Eia ka ʻOihana Honua ma ka Halemai Oncology ʻĀpana Hema o Beijing e kū pū me ʻoe i ke kaua ʻana i ka maʻi kanesa.
Ka manawa hoʻouna: Pepeluali-25-2026